Production of granulocyte colony-stimulating factor in the nonspecific acute phase response enhances host resistance to bacterial infection

Journal of Immunology

Volumn 169, Issue 2, 2002, Pages 913-919

  Noursadeghi, Mahdad ^a   Bickerstaff, Maria C M ^a   Herbert, Jeff ^a   Moyes, David ^a   Cohen, Jonathan ^a   Pepys, Mark B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESCHERICHIA COLI; HOST RESISTANCE; IMMUNOREACTIVITY; INFECTION RESISTANCE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0037100364     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.2.913     Document Type: Article

References (27)

1. Overview of resistance in the 1990s
2. The acute phase response and C-reactive protein
3. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein
4. The acute phase response and enhancing resistance to bacterial infection
5. Differences in the acute phase responses of serum amyloid P component (SAP) and C3 to injections of casein or bovine serum albumin in amyloid-susceptible and resistant mouse strains
6. Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice
7. Studies in vivo of cobra factor and murine C3
8. Streptococcal pyrogenic exotoxin A release, distribution, and role in a murine model of fasciitis and multiorgan failure due to Streptococcus pyogenes
9. Prophylactic and therapeutic effects of a monoclonal antibody to tumor necrosis factor-α in experimental Gram-negative shock
10. Simultaneous flow cytometric method to measure phagocytosis and oxidative products by neutrophils
11. Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker
12. Endotoxin tolerance: In vivo regulation of tumor necrosis factor and interleukin-1 synthesis is at the transcriptional level
13. Immunopathogenesis of severe sepsis
14. Phenotypic and functional characterization of mice that lack the type I receptor for IL-1
15. Impaired immune and acute-phase responses in interleukin-6-deficient mice
16. Granulocyte colony-stimulating factor and its receptor
17. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization
18. 1-acid glycoprotein in nonspecific resistance to a lethal Gram-negative infection
19. Recombinant human granulocyte colony-stimulating factor and Pseudomonas burn wound sepsis
20. Therapeutic efficacy of granulocyte colony-stimulating factor alone and in combination with antibiotics against Pseudomonas aeruginosa infections in mice
21. Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats
22. Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice
23. Treatment of intra-abdominal infection with granulocyte colony-stimulating factor
24. Filgrastim (r-metHuG-CSF): The first 10 years
25. American Society of Clinical Oncology guidelines for the use of hematopoietic colony-stimulating factors
26. A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia
27. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection